blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3818179

EP3818179 - EPIGENETIC METHOD TO DETECT AND DISTINGUISH IPEX AND IPEX-LIKE SYNDROMES, IN PARTICULAR IN NEWBORNS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  24.05.2024
Database last updated on 19.10.2024
FormerThe patent has been granted
Status updated on  16.06.2023
FormerGrant of patent is intended
Status updated on  20.02.2023
FormerExamination is in progress
Status updated on  18.02.2022
FormerRequest for examination was made
Status updated on  09.04.2021
FormerThe international publication has been made
Status updated on  11.01.2020
Formerunknown
Status updated on  13.08.2019
Most recent event   Tooltip02.08.2024Lapse of the patent in a contracting state
New state(s): SI		published on 04.09.2024  [2024/36]
Applicant(s)For all designated states
Precision for Medicine GmbH
Barbara-McClintock-Straße 6
12489 Berlin / DE
For all designated states
The Board of Trustees of the Leland Stanford Junior University
Building 170, Third Floor, Main Quad
P.O. Box 20386
Stanford, CA 94305-2038 / US
[2022/10]
Former [2021/19]For all designated states
Precision for Medicine GmbH
Barbara-McClintock-Straße 6
12489 Berlin / DE
Inventor(s)01 / OLEK, Sven
Boothstrasse 16
12207 Berlin / DE
02 / BACCHETTA, Rosa
134 Sandhill Circle
Menlo Park, California 94025 / US
 [2021/19]
Representative(s)Krauss, Jan
SKM-IP PartGmbB
Oberanger 45
80331 München / DE
[2023/29]
Former [2021/19]Krauss, Jan
Boehmert & Boehmert
Anwaltspartnerschaft mbB
Pettenkoferstrasse 22
80336 München / DE
Application number, filing date19748685.503.07.2019
[2021/19]
WO2019EP67918
Priority number, dateUS201862694149P05.07.2018         Original published format: US 201862694149 P
[2021/19]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020007951
Date:09.01.2020
Language:EN
[2020/02]
Type: A1 Application with search report 
No.:EP3818179
Date:12.05.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 09.01.2020 takes the place of the publication of the European patent application.
[2021/19]
Type: B1 Patent specification 
No.:EP3818179
Date:19.07.2023
Language:EN
[2023/29]
Search report(s)International search report - published on:EP09.01.2020
ClassificationIPC:C12Q1/6883
[2021/19]
CPC:
C12Q1/6883 (EP,US); C12Q1/686 (US); C12Q2600/112 (EP,US);
C12Q2600/154 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/19]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:EPIGENETISCHES VERFAHREN ZUM NACHWEIS UND ZUR UNTERSCHEIDUNG VON IPEX- UND IPEX-ÄHNLICHEN SYNDROMEN, INSBESONDERE BEI NEUGEBORENEN[2021/19]
English:EPIGENETIC METHOD TO DETECT AND DISTINGUISH IPEX AND IPEX-LIKE SYNDROMES, IN PARTICULAR IN NEWBORNS[2021/19]
French:MÉTHODE ÉPIGÉNÉTIQUE POUR DÉTECTER ET FAIRE LA DISTINCTION ENTRE DES SYNDROMES IPEX ET DES SYNDROMES DE TYPE IPEX, EN PARTICULIER CHEZ LES NOUVEAU-NÉS[2021/19]
Entry into regional phase14.01.2021National basic fee paid 
14.01.2021Designation fee(s) paid 
14.01.2021Examination fee paid 
Examination procedure14.01.2021Examination requested  [2021/19]
14.01.2021Date on which the examining division has become responsible
31.08.2021Amendment by applicant (claims and/or description)
21.02.2022Despatch of a communication from the examining division (Time limit: M04)
21.06.2022Reply to a communication from the examining division
21.02.2023Communication of intention to grant the patent
06.06.2023Fee for grant paid
06.06.2023Fee for publishing/printing paid
06.06.2023Receipt of the translation of the claim(s)
Opposition(s)22.04.2024No opposition filed within time limit [2024/26]
Fees paidRenewal fee
15.07.2021Renewal fee patent year 03
23.06.2022Renewal fee patent year 04
12.06.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT19.07.2023
CZ19.07.2023
DK19.07.2023
EE19.07.2023
ES19.07.2023
FI19.07.2023
HR19.07.2023
IT19.07.2023
LT19.07.2023
LV19.07.2023
NL19.07.2023
PL19.07.2023
RO19.07.2023
RS19.07.2023
SE19.07.2023
SI19.07.2023
SK19.07.2023
SM19.07.2023
NO19.10.2023
GR20.10.2023
IS19.11.2023
PT20.11.2023
[2024/36]
Former [2024/26]AT19.07.2023
CZ19.07.2023
DK19.07.2023
EE19.07.2023
ES19.07.2023
FI19.07.2023
HR19.07.2023
IT19.07.2023
LT19.07.2023
LV19.07.2023
NL19.07.2023
PL19.07.2023
RO19.07.2023
RS19.07.2023
SE19.07.2023
SK19.07.2023
SM19.07.2023
NO19.10.2023
GR20.10.2023
IS19.11.2023
PT20.11.2023
Former [2024/23]AT19.07.2023
CZ19.07.2023
DK19.07.2023
EE19.07.2023
ES19.07.2023
FI19.07.2023
HR19.07.2023
LT19.07.2023
LV19.07.2023
NL19.07.2023
PL19.07.2023
RO19.07.2023
RS19.07.2023
SE19.07.2023
SK19.07.2023
SM19.07.2023
NO19.10.2023
GR20.10.2023
IS19.11.2023
PT20.11.2023
Former [2024/22]AT19.07.2023
CZ19.07.2023
DK19.07.2023
FI19.07.2023
HR19.07.2023
LT19.07.2023
LV19.07.2023
NL19.07.2023
PL19.07.2023
RO19.07.2023
RS19.07.2023
SE19.07.2023
SM19.07.2023
NO19.10.2023
GR20.10.2023
IS19.11.2023
PT20.11.2023
Former [2024/20]AT19.07.2023
FI19.07.2023
HR19.07.2023
LT19.07.2023
LV19.07.2023
NL19.07.2023
PL19.07.2023
RS19.07.2023
SE19.07.2023
SM19.07.2023
NO19.10.2023
GR20.10.2023
IS19.11.2023
PT20.11.2023
Former [2024/10]AT19.07.2023
FI19.07.2023
HR19.07.2023
LT19.07.2023
LV19.07.2023
NL19.07.2023
PL19.07.2023
RS19.07.2023
SE19.07.2023
NO19.10.2023
GR20.10.2023
IS19.11.2023
PT20.11.2023
Former [2024/09]AT19.07.2023
FI19.07.2023
LT19.07.2023
NL19.07.2023
SE19.07.2023
NO19.10.2023
GR20.10.2023
IS19.11.2023
Former [2024/08]LT19.07.2023
NL19.07.2023
NO19.10.2023
GR20.10.2023
Former [2024/05]NL19.07.2023
Cited inInternational search[XY]EP1826279  (CHARITE UNIVERSITAETSMEDIZIN [DE], et al) [X] 14 * the whole document * * para. 37-39, claims 20-21 * [Y] 1-13,15;
 [YD]CN101768589  (UNIV PLA 3RD MILITARY MEDICAL) [YD] 1-15 * the whole document *;
 [XI]  - F. BARZAGHI ET AL, "Demethylation analysis of the FOXP3 locus shows quantitative defects of regulatory T cells in IPEX-like syndrome", JOURNAL OF AUTOIMMUNITY, GB, (20120201), vol. 38, no. 1, doi:10.1016/j.jaut.2011.12.009, ISSN 0896-8411, pages 49 - 58, XP055619260 [X] 1-11,14,15 * the whole document * * p. 54-55, item 3.4; Fig. 3C * [I] 12,13
 [XY]  - UDO BARON ET AL, "DNA demethylation in the humanFOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells", EUROPEAN JOURNAL OF IMMUNOLOGY, Weinheim, (20070901), vol. 37, no. 9, doi:10.1002/eji.200737594, ISSN 0014-2980, pages 2378 - 2389, XP055619397 [X] 14 * the whole document * * p. 2386, col. 2 - p. 2388, col. 2 * [Y] 1-13,15
 [YD]  - BARBARO MICHELA ET AL, "Newborn Screening for Severe Primary Immunodeficiency Diseases in Sweden-a 2-Year Pilot TREC and KREC Screening Study", JOURNAL OF CLINICAL IMMUNOLOGY, KLUWER ACADEMIC PUBLISHERS, NEW YORK, vol. 37, no. 1, doi:10.1007/S10875-016-0347-5, ISSN 0271-9142, (20161121), pages 51 - 60, (20161121), XP036131505 [YD] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1007/s10875-016-0347-5
by applicantWO2010000474
 CN101768589
 WO2012162660
 WO2017203048
 US9926599
    - MICHAEL J. BOOTH et al., Quantitative Sequencing of 5-Methylcytosine and 5-Hydroxymethylcytosine at Single-Base Resolution Science, (20120518), vol. 336, no. 6083, pages 934 - 937
    - ANTEQUERABIRD, Proc Natl Acad Sci USA, (19930000), vol. 90, pages 11995 - 9
    - JONESLAIRD, Nature Genetics, (19990000), vol. 21, pages 163 - 167
    - ESTELLER, Oncogene, (20020000), vol. 21, pages 5427 - 5440
    - LAIRD, Nature Reviews/Cancer, (20030000), vol. 3, pages 253 - 266
    - BARZAGHI F et al., "Demethylation analysis of the FOXP3 locus shows quantitative defects of regulatory T cells in IPEX-like syndrome", J Autoimmun., (20120200), vol. 38, no. 1, pages 49 - 58
    - WILLIAMS L et al., "DNA hypermethylation of CD3(+) T cells from cord blood of infants exposed to intrauterine growth restriction", Diabetologia, (20160800), vol. 59, no. 8, doi:doi:10.1007/s00125-016-3983-7, pages 1714 - 23, XP036237787

DOI:   http://dx.doi.org/10.1007/s00125-016-3983-7
    - Cancer Diagnostics, Prognostics, and Response to Treatment Clinical Chemistry, (20090000), vol. 55, no. 8, pages 1471 - 1483
    - M. BARBARO et al., "Newborn Screening for Severe Primary Immunodeficiency Diseases in Sweden-a 2-Year Pilot TREC and KREC Screening Study", J. Clin. Immunol., (20170000), vol. 37, doi:doi:10.1007/s10875-016-0347-5, pages 51 - 60, XP036131505

DOI:   http://dx.doi.org/10.1007/s10875-016-0347-5
    - U. BARON et al., "DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells", Eur. J. Immunol., (20070000), vol. 37, doi:doi:10.1002/EJI.200737594, pages 2378 - 2389, XP002503237
    - A. BOLDT et al., "Eight-color immunophenotyping of T-, B-, and NK-cell subpopulations for characterization of chronic immunodeficiencies", Cytom. Part B - Clin. Cytom., (20140000), vol. 86, doi:doi:10.1002/cyto.b.21162, pages 191 - 206, XP055254566

DOI:   http://dx.doi.org/10.1002/cyto.b.21162
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.